SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of antidiabetic medication that inhibit the absorption of glucose from the proximal tubule of the kidney and hence cause glycosuria. Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated hemoglobin by 0.5%–1.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function. More importantly, SGLT2i have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms underlying their cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+/H+ exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis. The main adverse events of SGLT2i include urinary tract and genital infections, as well as euglycemic diabetic ketoacidosis. Concerns have also been raised about the association of SGLT2i with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2-i improves the metabolic profile in patients with diabetes increasing glycosuria by inhibiting glucose reuptake in the renal proximal tubule. As a result, they induce a reduction of both arterial pressure and body weight, demonstrating impressive cardio- and nephro-protective effects [59].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 10×
“The EMPA-REG OUTCOME trial and the CANVAS program showed that the administration of Empa or Cana increased both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) when compared with placebo [65,68].”
BackgroundMethodResultInfluentialAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 5×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundInfluentialOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 14×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundMethodResultInfluential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 10×
“Results of DECLARE-TIMI, nevertheless, did not confirm a higher cancer risk with Dapa [69].”
BackgroundMethodResultInfluentialCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“Administration of Cana led to the reduction of end-stage renal disease, doubling of the serum creatinine level, or death from renal or CV causes [85].”
Background
Cited by
Items 101–200 of 325
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Diabetes mellitus and multiple myeloma; common features of two distinct entities
Tentolouris, A., Ntanasis‐Stathopoulos, I., Eleftheriadou, I., Malandrakis, P., Tzeravini, E., & Gavriatopoulou, M. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3535 · Cited by 16
“In terms of antidiabetic medication, sodium‐ glucose cotransporter (SGLT) two inhibitors (SGLT2i) should be administered to people with Τ2DM and diabetic CKD and albuminuria.(32,35) In addition, in people with CKD who are at increased risk for CV events, the use of SGTL2i or glucagon‐like peptide 1 receptor agonist (G…”
BackgroundSelf-citationLeancă, S. A., Afrăsânie, I., Crișu, D., Matei, I. T., Duca, Ș.-T., Costache, A. D., Aursulesei, V. O., Tudorancea, I., Mitu, O., Bădescu, M. C., et al. (2023) · Life · doi:10.3390/life13041000 · Cited by 18
“In addition, SGLT2 inhibitors suppress pro-fibrotic markers, such as type 1 collagen and MMPs, and attenuate TGF-β1-induced fibroblast activation, thus reducing myocardial fibrosis [110,111].”
BackgroundProximal myopathy: causes and associated conditions
Rao, A., Nawaz, I., Arbi, F. M., & Ishtiaq, R. (2022) · Discoveries · doi:10.15190/d.2022.19 · Cited by 14
Shah, S., Mushahid, H., Salman, A., Farhan, S. H., Latif, F., Siddiqi, R. L., Nashwan, A. J., Abramov, D., & Minhas, A. M. K. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01183-8 · Cited by 13
“These adverse events are likely attributed to the glycosuric mechanism of action of SGLT2i [44, 45].”
A step-by-step guide for the diagnosis and management of hyponatraemia in patients with stroke
Barkas, F., Anastasiou, G., Liamis, G. L., & Milionis, H. J. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231163806 · Cited by 13
Goto, S., Ishikawa, J., Idei, M., Iwabuchi, M., Namekawa, M., & Nomura, T. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.929773 · Cited by 16
“SGLT2is decrease glycated hemoglobin, body weight, and blood pressure [1,2].”
BackgroundSia, C. S. M., Leong, L. C. Y., Wong, E. T. Y., Goh, G. H., & Leo, C. C. H. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2020526 · Cited by 12
Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Jing, Y., Yang, R., Chen, W., & Ye, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.898718 · Cited by 12
Xiang, L., Liu, M., Xiang, G., Yue, L., Zhang, J., Xu, X., & Dong, J. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00747-5 · Cited by 13
“Multiple pre-clinical and clinical studies have demonstrated that SGLT2 inhibitors are benefit for patients with cardiovascular disease, coronary artery disease, and heart failure with or without reduced ejection fraction [6, 7].”
BackgroundZhang, Q., Deng, Z., Li, T., Chen, K., & Zeng, Z. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1280547 · Cited by 14
“Adverse events might occur with SGLT2 inhibitors including an increased risk of orthostatic hypotension, urinary tract infection, diabetic ketoacidosis, renal impairment, and possibly limited amputations (161 – 163).”
BackgroundHe, X., Li, Y., Li, Y., Guo, C., Fu, Y., Xun, X., Wang, Z., & Dong, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114663 · Cited by 12
Kannan, K., George, J. A., Sahadevan, R., Kothari, M., & Sadhukhan, S. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-10047-9 · Cited by 12
“Its role in reabsorbing filtered glucose is critical, and inhibiting this transporter can help manage blood glucose levels (Tentolouris et al. 2019).”
Koch, B., Fuhrmann, D. C., Schubert, R., Geiger, H., Speer, T., & Baer, P. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031811 · Cited by 11
Marcińczyk, N., Misztal, T., Chabielska, E., & Gromotowicz‐Poplawska, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-28225-8 · Cited by 10
Olusola, A. J., Famuyiwa, S. O., Faloye, K. O., Olatunji, O. E., Olayemi, U. I., Adeyemi, A. A., Balogun, J. O., Ogundele, S. B., Babamuyiwa, B. O., & Patil, R. B. (2024) · Bioinformatics and Biology Insights · doi:10.1177/11779322231223851 · Cited by 10
SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective
KUMAR, K. M. P., Unnikrishnan, A., Jariwala, P. V., Mehta, A., Chaturvedi, R., Panchal, S., Lakhani, P., Acharya, R., & Dixit, J. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_377_23 · Cited by 11
Megalin Knockout Reduces SGLT2 Expression and Sensitizes to Western Diet-induced Kidney Injury
Youm, E. B., Shipman, K. E., Albalawy, W. N., Vandevender, A. M., SIPULA, I. J., Rbaibi, Y., Marciszyn, A. L., Lashway, J., Brown, E. E., Bondi, C. D., et al. (2024) · Function · doi:10.1093/function/zqae026 · Cited by 10
Du, J., Shen, M., Chen, J., Yan, H., Xu, Z., Yang, X., Yang, B., Luo, P., Ding, K., Hu, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1510080 · Cited by 11
Loh, H. H., Tay, S. P., Koa, A. J., Yong, M. C., Said, A., Chai, C.-S., Malik, N. M. A., Su, A. T., Tang, B. B. C., Tan, F. H. S., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06312-w · Cited by 10
“It works by inducing glycosuria and is known to reduce HbA1c and blood pressure (BP) in addition to increasing HDL and LDL while decreasing triglycerides [22].”
Kongmalai, T., Prawjaeng, J., Hadnorntun, P., Leelahavarong, P., Chaikledkaew, U., Thakkinstian, A., & Srinonprasert, V. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00526-2 · Cited by 10
“Although these medications share a similar mechanism of action, they differ in terms of molecular structure, pharmacokinetics, pharmacodynamics, selectivity for the SGLT-1/ SGLT-2 receptor, ability to reduce CV events in clinical trials, and price [11].”
Zhang, J., Ye, X.-R., Liu, X., Zhang, H.-L., & Qiao, Q. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i1.101491 · Cited by 11
Updates in pharmacotherapy of heart failure with reduced ejection fraction
Espinoza, C., Alkhateeb, H., & Siddiqui, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4640 · Cited by 9
“Less common but serious adverse reactions include the risk for diabetic ketoacidosis as well as an increased risk of lower limb amputation, mainly of the toes, and a possible risk for Fournier gangrene (41).”
BackgroundMedications for gout and its comorbidities: mutual benefits?
Yoshida, K., Choi, H. K., & Solomon, D. H. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000784 · Cited by 9
“In the current diabetes guideline, [74] SGLT2i is recommended after dietary modification, exercise, and metformin (first-line for all) in patients high risk or with atherosclerotic CVD, CKD, or heart failure [73].”
BackgroundAhmed, G., Abed, M. N., & Alassaf, F. A. (2023) · Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ · doi:10.33899/iphr.2023.137946.1041 · Cited by 14
Prasad, M. K., Victor, P., Ganesh, G. V., Juttada, U., Kumpatla, S., Viswanathan, V., & Ramkumar, K. M. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2465 · Cited by 9
Patoulias, D., Papadopoulos, C. E., Zografou, I., Katsimardou, A., Karagiannis, A. I., & Doumas, M. N. (2022) · Medicina · doi:10.3390/medicina58091167 · Cited by 10
Derobertmasure, A., Toh, L. S., Wotring, V. E., Williams, P. M., Morbidelli, L., Stingl, J., Vinken, M., Ramadan, R., Chhun, S., & Boutouyrie, P. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107063 · Cited by 10
Wen, J., & Chen, C. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10412-7 · Cited by 8
“The drug reduced glucose reabsorption in the proximal tubule of the kidney by inhibiting SGLT2, thereby lowering blood glucose, reducing insulin resistance, and protecting pancreatic β-cells [95, 96].”
Ren, J., Chen, X., Wang, T., Liu, C.-Y., & Wang, K. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1533105 · Cited by 8
Ju, F., Abbott, G. W., Li, J., Wang, Q., Liu, T., Liu, Q., & Hu, Z. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07419-8 · Cited by 9
“SGLT2 inhibitors exert their glucose-lowering effect by reducing glucose reabsorption in the renal proximal tubule [3].”
Impact of tofogliflozin on hepatic outcomes: a systematic review
Pathak, M., Parveen, R., Khan, P. M., Saha, N., & Agarwal, N. B. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03537-w · Cited by 8
“This indicates the wide range of the benefits of SGLT2 inhibitors that extend beyond any other anti-diabetic drug [47, 48].”
BackgroundKuoni, S., Müller, D., Simões‐Wüst, A. P., & Steiner, R. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123841 · Cited by 8
Canagliflozin: metabolic, Cardiovascular and Renal Protection
Barrios, V., & Escobar, C. (2021) · Future Cardiology · doi:10.2217/fca-2020-0192 · Cited by 8
Güldan, M., Özbek, L., Abdel‐Rahman, S. M., Narin, A. E., Orak, H. İ., Goren, H. K., Afşar, B., Rossing, P. R., & Kanbay, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70019 · Cited by 7
“75 SGLT2i appear to impact these fat depots through mechanisms that are independent of general body weight reduction, highlighting their potential cardiometabolic and renal benefits 76 (Figure 2).”
Translating Metabolic Interventions into Breast Cancer Therapy: A Comprehensive Review
Chen, L., Shiao, S. L., & Yuan, Y. (2025) · Life · doi:10.3390/life15101634 · Cited by 7
“Mechanistically, SGLT2 blockade reduces renal glucose reuptake, induces glycosuria, and lowers plasma glucose levels through an insulin-independent mechanism, an important advantage in patients with impaired β -cell function or insulin resistance [84].”
Jisha Pillai, U., Singh, P., Maan, M., Jayakumar, M. N., Donakonda, S., Iype, E., & Dutta, M. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118340 · Cited by 7
Khalid, A., Balach, R., Rasool, A., Daniyal, S. M., Nizami, M. T., Gul, I., Naqvi, A., Fonarow, G. C., & Waqas, S. A. (2026) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2026.106138 · Cited by 7
Li, S., Wang, L., Wang, P., Xu, X., & Guo, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1594861 · Cited by 10
“Dapagli fl ozin, an SGLT2 inhibitor, promotes diuresis and natriuresis, which reduces preload and afterload, thereby lowering myocardial workload (35, 36).”
Hiyama, Y., Sato, T., Takahashi, S., Yamamoto, S., Ogasawara, N., Masumori, N., & Yokota, S. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115556 · Cited by 9
Hussain, M., Hussain, A., Rehman, H. U., & Iqbal, J. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2115102804 · Cited by 8
Zhao, Y.-X., Borjigin, S., & Yan, Z.-L. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.224 · Cited by 7
Yared, K., & Mancini, G. J. (2020) · The American Surgeon · doi:10.1177/0003134820940286 · Cited by 7
Aftab, S., Suresh, R. V., Sherali, N., Daniyal, M., & Tsouklidis, N. (2020) · Cureus · doi:10.7759/cureus.10783 · Cited by 7
“All the effects eventually provide benefits to patients with T2DM and lead to improved ventricular volume load, cardiac muscle cell function, and diastolic function of the left cardiac ventricle, as left ventricular diastolic dysfunction is a usual pathologic finding in T2DM patients with heart failure [3].”
BackgroundStone, C. R., Harris, D. D., Broadwin, M., Sabe, S. A., Bellam, K. G., Kanuparthy, M., Abid, M. R., & Sellke, F. W. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.09.065 · Cited by 6
Nakatani, D., Dohi, T., Hikoso, S., Tanaka, A., Nanasato, M., Shimizu, W., Node, K., Sakata, Y., & on behalf of the CANDLE Trial Investigators (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001430 · Cited by 6
“DISCUSSION This post-hoc analysis of the CANDLE trial showed that: (1) canagliflozin was associated with a hematopoietic effect independent of volume status and the characteristics of the patient; (2) hematopoiesis associated with canagliflozin was apparent after 1 month, augmented at 3 months, and continued up to 6 m…”
MethodInvestigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus
Cui, H., Luo, X., Chen, M., Lu, J., & Liu, J. J. (2023) · Current Drug Targets · doi:10.2174/1389450124666230503120930 · Cited by 6
Abouelenein, D., Caprioli, G., & Mustafa, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-030-94753-8_25-1 · Cited by 7
Correale, M., Mazzeo, P., Fortunato, M., Paradiso, M., Furore, A., Fanizzi, A. I., Tricarico, L., Pastore, G., Alfieri, S., Brunetti, N. D., et al. (2023) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12857 · Cited by 6
“…to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na + / H + exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis (Tentolouris et al., 2019).”
BackgroundYang, P., Wang, P.-H., Huang, J., Lee, C., Lin, C.-W., Lee, C., & Yang, S. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.95584 · Cited by 6
“Except for anti-hyperglycemic ability, SGLT2 inhibitors can prevent other morbidities based on earlier literatures [4, 6].”
BackgroundInfluentialGautier, P., Elbaz, M., Bouisset, F., Despas, F., & Montastruc, F. (2025) · Drug Safety · doi:10.1007/s40264-025-01546-5 · Cited by 7
“Safety data regarding SGLT-2is and their association with cancer are currently contradictory and debated, particularly with bladder cancer [4].”
Tsyvunin, V., Shtrygol’, S., Havrylov, I., Shtrygol, D. V., & Reus, A. (2022) · ScienceRise Pharmaceutical Science · doi:10.15587/2519-4852.2022.266065 · Cited by 6
“Attention is drawn to the polymodal properties of a new class of antidiabetic medicines – the sodium-glucose transport protein 2 (SGLT-2) inhibitors, which suppress the reabsorption of glucose in the tubules of the kidneys [19].”
Yaginuma, H., Banno, R., Sun, R., Taki, K., Mizoguchi, A., Kobayashi, T., Sugiyama, M., Tsunekawa, T., Onoue, T., Takagi, H., et al. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.08.010 · Cited by 6
Bilgin, S., Duman, T. T., Kurtkulağı, Ö., Yilmaz, F., & Aktaş, G. (2022) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2022.07.928 · Cited by 7
Kamrul-Hasan, A. B. M., Mondal, S., Aalpona, F. T. Z., Nagendra, L., & Dutta, D. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.2 · Cited by 10
“22 Reducing glucotoxicity and lipotoxicity can improve beta-cell function to some extent.”
Zhao, C., Guo, Y., Wang, R., Cheng, C., & Chen, X. (2021) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2021.25.6.517 · Cited by 6
Saiti, A., Giannopoulos‐Dimitriou, A., Kazakos, I., Galatou, E., & Vizirianakis, I. S. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010021 · Cited by 5
Kwak, S. H., Han, K. A., Kim, E. S., Choi, S. H., Won, J. C., Yu, J. M., Oh, S., Yoo, H. J., Kim, C. H., Kim, K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15738 · Cited by 5
“7 10 Enavogliflozin, a recently developed and commercialized drug, is a novel selective SGLT2 inhibitor.”
Popoviciu, M. S., Salmen, T., Reurean‐Pintilei, D., Voiculescu, V. M., & Stoian, A. P. (2025) · Medicina · doi:10.3390/medicina61030548 · Cited by 5
“For example, empagliflozin has a higher affinity for SGLT2 receptors, resulting in greater glucose excretion and, consequently, a possible higher calorie loss compared to dapagliflozin [71,72].”
Gupta, S., Dubey, S., Patel, S., Lakra, A. P., & Minz, S. (2025) · Journal of Applied Pharmaceutical Research · doi:10.69857/joapr.v13i2.1006 · Cited by 5
Chung, J.-F., Yang, P.-J., Chang, C., Lee, C., Huang, J., Wang, K., & Yang, S. (2024) · Archives of Medical Science · doi:10.5114/aoms/174228 · Cited by 5
Monda, V. M., Porcellati, F., Strollo, F., Fucili, A., Monesi, M., Satta, E., & Gentile, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01791-x · Cited by 6
Johri, N., Matreja, P. S., John, D., Dutta, S., Parida, A. K., & Sarma, S. N. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221017123333 · Cited by 5
Ma, S., He, L., Zuo, Q., Zhang, G., & Guo, Y. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2022.0024 · Cited by 9
Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
Bilal, A., & Pratley, R. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.010 · Cited by 5
Emerging insights into the role of visceral adipose tissue in diabetic kidney disease
Li, L., Liu, C., & Gu, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1715701 · Cited by 4
“Their nephroprotective mechanisms extend beyond hypoglycemia, with VAT reduction and subsequent mitigation of lipotoxicity, inflammation, and hemodynamic dysregulation being key contributors (101, 117).”
Talwar, A., Nayyar, A., Anand, S., Zahera, M., & Singh, P. (2025) · Asian Journal of Chemistry · doi:10.14233/ajchem.2025.34663 · Cited by 4
Tentolouris, A., Koufakis, T., & Fousteris, E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00693-9 · Cited by 5
“Sodium-glucose cotransporter-2 (SGLT2) inhibitors they are approved for the treatment of T2DM, heart failure and chronic kidney disease [101].”
Self-citationEdwards, A., Singh, P., Shah, V., Chander, V., & Mishra, S. (2026) · Cells · doi:10.3390/cells15060529 · Cited by 5
“Sodium-glucose co-transporter-2 (SGLT2) inhibitors promote glycosuria to reduce hyperglycemia and provide additional cardioprotective benefits, including lowering blood pressure and reducing hospitalizations for heart failure [145].”
Salmen, T., Rizvi, A. A., Rizzo, M., Pietroșel, V.-A., Bica, I.-C., Diaconu, C.-T., Potcovaru, C.-G., Salmen, B.-M., Coman, O. A., Bobirca, A. V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092455 · Cited by 5
“5% to 1% [42], but the reduction can be larger as, for example, in a meta-analysis by Masson W et al.”
BackgroundČináková, A., Křenek, P., Klimas, J., & Kráľová, E. (2023) · Pharmacology · doi:10.1159/000533592 · Cited by 4
“Moreover, dapagli fl ozin was shown to acutely improve arterial stiffness, most probably via its direct effect on the vascular endothelium and oxidative stress reduction [11].”
BackgroundXBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions
Sun, Y., Zhang, Y., Zhang, J., Chen, Y. E., Jin, J., Zhang, K., Mou, H., Liang, X., & Xu, J. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01203-x · Cited by 4
Kolesnyk, M. Y., & Maistrovych, Y. Y. (2024) · Modern medical technology · doi:10.14739/mmt.2024.1.296545 · Cited by 4
Sodium‐glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside
Bagheri, B., Yaribeygi, H., Taherifard, E., Talasaz, A. H., Bagheri, H., Darban, M., Tabrizi, R., Najafi, S., Khodadost, M., & Akbari, M. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12852 · Cited by 4
“In addition to their roles in the glucose homeostasis, SGLT2is provide protective effects for cardiovascular and renal systems.(1,3) Phlorizin, an O-glucoside of phloretin, was the first natural compound with SGLT2 inhibitory effects and was primarily isolated from the apple tree, mostly from its vegetative tissues, a…”
BackgroundYao, Y.-P., Yang, P., Lee, C., Huang, J., Yang, S., & Lin, H. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.88720 · Cited by 4
“Specifically, the occurrence and progression of coronary heart disease can be retarded by the use of SGLT2 inhibitors [4].”
BackgroundDiabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice
Bafna, A. A., Mehta, A., Garg, R., Balagopalan, J. P., Rajput, R., Zalte, N., Naik, P., Sugumaran, A., & Mohanasundaram, S. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_115_23 · Cited by 5
Basutkar, R. S., Cutinha, R. M., Sathish, V., Shahil, A., & Najad Saneen, C. K. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998301228240625065230 · Cited by 4
Tsai, T.-Y., Yang, P., Chao, S.-C., Lee, C., Huang, J., Yang, S., & Lin, H. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.91571 · Cited by 4
“In addition to the anti-diabetic effectiveness, the SGLT2 inhibitors also revealed protective function on certain other organs [3, 6].”
BackgroundInfluentialRecent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
de Matos, A. M., Calado, P., Washburn, W. N., & Rauter, A. P. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch4 · Cited by 6
Doğruel, H., Atlım, H. T., Aydemir, M., Yılmaz, N., & Sarı, R. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03262-w · Cited by 4
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
“6,69 72 Also, due to the atherosclerosis process, diabetic patients are prone to ischemic heart diseases.”
BackgroundNguyen, N. K., Nguyen, H. T. T., Phuong, T., Trịnh, Q. V., Duong, N. T., Pham, P. X., & Anh, P. T. V. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100819 · Cited by 5
Khan, A. U., Sharif, M. J. H., Ashfaq, M., Khan, Q., Iqbal, M. M., Iqbal, A., Bashatah, A., Syed, W., & Alqahtani, N. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01041-8 · Cited by 4
“Dipeptidyl peptidase - IV (DPP-IV) enzyme is present in plasma soluble form and membrane bound form [1, 2, 5].”
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure
Mamand, S., & Mustafa, Z. A. (2023) · Polytechnic Journal · doi:10.25156/ptj.v12n2y2022.pp53-60 · Cited by 3
Gu, A., Zhang, C., Li, D., Cen, B., Cao, W., & Xu, Z. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70108 · Cited by 3
Unlusoy, Y. B., Dizdar, O. S., & Günal, A. İ. (2025) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0485 · Cited by 3
“Sodium-glucose cotransporter 2 inhibitors (SGLT2is) act by inhibiting the reabsorption of glucose from the kidney’s proximal tubule, resulting in glycosuria (5).”
Gill, G. S., Latif, A., Hilleman, D. E., Lavie, C. J., & Alla, V. M. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100878 · Cited by 4
Bezerra, T. G., Gonçalves, A. L. G., Franco, A. M., Rossi, B. A., Gazzoni, G. A. S., Winter, M. L., Marques, M. O., Bark, S., Cruz, V. S., & Rêgo, R. C. L. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e6890.2021 · Cited by 5
Tahara, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174486 · Cited by 3
Zaawari, A., & Sahar, A. N. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104536 · Cited by 3
“Glucagon peptide-1 receptor agonists (GLP1-RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), on the other hand, have shown cardioprotective and renoprotective benefits, besides decreasing cardiovascular outcomes [5,6].”
BackgroundBiotherapeutic approaches against cardio-metabolic dysfunctions based on extracellular vesicles
Marchal, S., Andriantsitohaina, R., & Martínez, M. C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167095 · Cited by 3
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Acute Coronary Syndrome
Song, J., Liu, Y., Xu, Y., & Hao, P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00076 · Cited by 3
Agrawal, P. K., Pursnani, N., Gautam, A., & Garg, R. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100076 · Cited by 3
Liu, X., Zhang, S., Chen, K., Che, J., & Li, C. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100181 · Cited by 3
“In clinical studies (such as the EMPA-REG OUTCOME trial and the CANVAS program), SGLT-2i have produced favorable cardio-vascular benefit outcomes through different possible mechanisms [13].”
BackgroundTsui, T.-L., Ho, Y., Ueng, K.-C., Liao, P., Huang, J., Lee, C., Su, S., & Yang, S. (2024) · Journal of Cancer · doi:10.7150/jca.101165 · Cited by 2
“In recent years, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been widely used for T2DM management, reducing hyperglycemia by 0.5% to 1.0% [4, 5].”
BackgroundInfluentialGenomic insights about the effect of sodium-glucose cotransporter 2 inhibitors: a systematic review
Kumar, P. S., Chidambaram, Y., Devi, G., Venkatesan, V., Sankaran, R., Senguttuvan, N. B., Thanikachalam, S., & Prabhakaran, D. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1571032 · Cited by 2
“Though it has signi fi cant cardio-reno protective actions, it is limited by an increased occurrence of urinary tract and vaginal infections, along with euglycemic diabetic ketoacidosis (Tentolouris et al., 2019).”
Liu, Y., Barner, J. C., Lawson, K. A., Liu, Y., & Park, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378245 · Cited by 2
“19,20 Several possible mechanisms were established to explain the cardioprotective effects of SGLT2i.”
Suciu, I. M., Mateoc-Sirb, T., Luca, C. T., Timar, B., & Gaiță, D. I. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031056 · Cited by 2
Manunta, M., Bruno, G. M., Ferrantelli, A., Ramirez, R. F., & Nardi, F. (2026) · Drugs in Context · doi:10.7573/dic.2026-1-1 · Cited by 3
Metadata
- Authors
- Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-08-17
- Volume
- 16
- Issue
- 16
- Pages
- 2965
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC6720282
- OpenAlex
- W2967960051
- Cited by
- 300
- References
- 183
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 55 · 2023: 54 · 2022: 54 · 2021: 40 · 2020: 26 · 2019: 2
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, cardioprotection, renal protection, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glycosuria, HbA1c, arterial stiffness, endothelial function, Na+/H+ exchange, myocardial fibrosis, adverse events, lower limb amputation, acute kidney injury, cardiovascular risk
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Cardiotonic Agents, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.